The emergence of immunotherapy has provided significant clinical improvements in the treatment of metastatic solid tumors. Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has dismal prognosis with median survival ranging between 6and12 months. Our aim is to review the current knowledge on the role of the immune system and immune checkpoint inhibitors in HNSCC. We will focus on the landmark trials that led to the regulatory approvals of pembrolizumab and nivolumab, and discuss a few promising contenders in clinical development and highlight the need to identify better biomarkers other than programmed death-ligand 1 to improve patient selection and help predict response.
SiegelRL, MillerKD, JemalA. Cancer Statistics, 2017. CA Cancer J Clin2017;67:7–30.doi:10.3322/caac.21387
2.
SaccoAG, CohenEE. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol2015;33:3305–13.doi:10.1200/JCO.2015.62.0963
3.
VermorkenJB, MesiaR, RiveraF, . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med2008;359:1116–27.doi:10.1056/NEJMoa0802656
4.
TongCC, KaoJ, SikoraAG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res2012;54(1-3):266–74.doi:10.1007/s12026-012-8306-6
5.
DunnGP, OldLJ, SchreiberRD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity2004;21:137–48.doi:10.1016/j.immuni.2004.07.017
6.
VeselyMD, KershawMH, SchreiberRD, . Natural innate and adaptive immunity to cancer. Annu Rev Immunol2011;29:235–71.doi:10.1146/annurev-immunol-031210-101324
7.
StraussL, BergmannC, GoodingW, . The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res2007;13:6301–11.doi:10.1158/1078-0432.CCR-07-1403
8.
ChikamatsuK, SakakuraK, WhitesideTL, . Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck2007;29:120–7.doi:10.1002/hed.20490
9.
FerrisRL, HuntJL, FerroneS, antigenHleukocyte. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res2005;33:113–34.doi:10.1385/IR:33:2:113
10.
FerrisRL, WhitesideTL, FerroneS. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res2006;12:3890–5.doi:10.1158/1078-0432.CCR-05-2750
11.
FerrisRL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol2015;33:3293–304.doi:10.1200/JCO.2015.61.1509
12.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012;12:252–64.doi:10.1038/nrc3239
13.
ZandbergDP, StromeSE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol2014;50:627–32.doi:10.1016/j.oraloncology.2014.04.003
14.
Lyford-PikeS, PengS, YoungGD, . Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res2013;73:1733–41.doi:10.1158/0008-5472.CAN-12-2384
15.
McCoyKD, Le GrosG. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol1999;77:1–10.doi:10.1046/j.1440-1711.1999.00795.x
16.
FerrisRL, BlumenscheinG, FayetteJ, . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med2016;375:1856–67.doi:10.1056/NEJMoa1602252
17.
ChowLQM, HaddadR, GuptaS, . Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol2016;34:3838–45.doi:10.1200/JCO.2016.68.1478
18.
BaumlJ, SeiwertTY, PfisterDG, . Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol2017;35:1542–9.doi:10.1200/JCO.2016.70.1524
19.
BaumanJE, CohenE, FerrisRL, . Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer2016.
20.
SeiwertTY, BurtnessB, MehraR, . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol2016;17:956–65.doi:10.1016/S1470-2045(16)30066-3
21.
PembrolizumabCEE. pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. ESMO Congress; Madrid, Spain2017.
22.
BrahmerJR, DrakeCG, WollnerI, . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol2010;28:3167–75.doi:10.1200/JCO.2009.26.7609
23.
TopalianSL, HodiFS, BrahmerJR, . Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med Overseas Ed2012;366:2443–54.doi:10.1056/NEJMoa1200690
24.
HarringtonKJ, FerrisRL, BlumenscheinG, . Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol2017;18:1104–15.doi:10.1016/S1470-2045(17)30421-7
25.
SegalSIO NH, BalmanoukianAS, MassarelliE, . Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, In Head and neck cancer. ESMO2016. Congress.
26.
Zandberg. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. ESMO2017. Congress.
27.
WolchokJD, RollinL, LarkinJ. Nivolumab and Ipilimumab in Advanced Melanoma. New Engl J Med2017;377:2503–4.
28.
MotzerRJ, TannirNM, McDermottDF, . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med Overseas Ed2018;378:1277–90.doi:10.1056/NEJMoa1712126
29.
JieHB, SchulerPJ, LeeSC, . CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res2015;75:2200–10.doi:10.1158/0008-5472.CAN-14-2788
30.
ParikhF, DulucD, ImaiN, . Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res2014;74:7205–16.doi:10.1158/0008-5472.CAN-14-1913
31.
VincentJ, MignotG, ChalminF, . 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res2010;70:3052–61.doi:10.1158/0008-5472.CAN-09-3690
32.
GhiringhelliF, LarmonierN, SchmittE, . CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol2004;34:336–44.doi:10.1002/eji.200324181
33.
BrixN, TiefenthallerA, AndersH, . Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev2017;280:249–79.doi:10.1111/imr.12573
34.
RiceAE, LatchmanYE, BalintJP, . An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther2015;22:454–62.doi:10.1038/cgt.2015.40
35.
LynchDH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev2008;222:277–86.doi:10.1111/j.1600-065X.2008.00621.x
36.
WeinbergAD, RiveraMM, PrellR, . Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol2000;164:2160–9.doi:10.4049/jimmunol.164.4.2160
37.
BellRB, LeidnerRS, CrittendenMR, . OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. Oral Oncol2016;52:1–10.doi:10.1016/j.oraloncology.2015.11.009
38.
DengWW, MaoL, YuGT, . LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology2016;5:e1239005.doi:10.1080/2162402X.2016.1239005
39.
GillenwaterAM, ZhongM, LotanR. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther2007;6:2967–75.doi:10.1158/1535-7163.MCT-04-0344
40.
BadoualC, HansS, MerillonN, . PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res2013;73:128–38.doi:10.1158/0008-5472.CAN-12-2606
41.
AngKK, HarrisJ, WheelerR, . Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med Overseas Ed2010;363:24–35.doi:10.1056/NEJMoa0912217
42.
MarurS, D'SouzaG, WestraWH, . HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol2010;11:781–9.doi:10.1016/S1470-2045(10)70017-6
43.
FakhryC, WestraWH, LiS, . Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst2008;100:261–9.doi:10.1093/jnci/djn011
44.
ChungCH, GillisonML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res2009;15:6758–62.doi:10.1158/1078-0432.CCR-09-0784
45.
FisherJW, ThompsonBM, GarciaAD. Integrative clinical experience: an innovative program to prepare for internship. Teach Learn Med2007;19:302–7.doi:10.1080/10401330701366788
46.
StromeSE, DongH, TamuraH, . B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res2003;63:6501–5.
